drugset / Trial / NCT04673630
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
Non-randomizedSingle-groupOpen-labelBasic science
Summary
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
Timeline
- Start
- 2021-02-23
- Primary completion
- 2022-09-27
- Completion
- 2022-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | — | Subcutaneous |